Biomarin Pharmaceutical Stock News

Here are the five best biotech ETFs to invest in right now.

Biomarin Pharmaceuticals's (BMRN) Voxzogo is the first medicine in the United States to be approved to treat achondroplasia, the most common form of dwarfism.

Over the past 3 months, 6 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ: BMRN ) stock.

Could these biotech stocks be poised for long-term gains?

Biomarin Pharmaceuticals's (BMRN) Voxzogo is the first medicine in the United States to be approved to treat achondroplasia, the most common form of dwarfism.

BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by equities research analysts at William Blair from a market perform rating to an outperform rating in a report issued on Monday, The Fly reports. Other analysts have also recently issued reports about the company. Jefferies Financial Group initiated coverage on BioMarin Pharmaceutical in a research note on Thursday, July []

BioMarin Pharmaceuticals Voxzogo is the first FDA approved therapy for achondroplasia, an inherited disorder that causes the most common form of dwarfism. With approvals in Europe and the U.S., and more regulatory decisions expected in 2022, the biotech said the drug has blockbuster potential.

Little People of America (LPA), the worlds oldest and largest support organization for people with dwarfism and their families, has been tracking biotechnical developments for the treatment of individuals with Achondroplasia. LPA President, Mark Povinelli, says, "With the FDA approval of BioMarins Voxzogo therapy, the dwarfism community has been challenged with the impact of this new treatment on [PR.com]

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 20, 2021 /Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you. INNV Shareholders Click Here: https://www.zlk.com/pslra-1/innovage-holding-inc-loss-submission-form-2?prid=21431&wire=1BMRN Shareholders Click Here: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21431&wire=1HMLP Shareholders Click Here: https://www.zlk.com/pslra-1/hoegh-lng-partners-lp-loss-submission-form?prid=21431&wire=1 * ADDITIONAL INFORMATION BELOW * InnovAe Holding Inc. (NASDAQ:INNV) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired InnovAge common stock ..

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 20, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn''t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CONTACT JAKUBOWITZ ABOUT BMRN:https://claimyourloss.com/securities/biomarin-pharmaceutical-inc-loss-submission-form-2/?id=21425&from=1 Class Period : January ..

The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo.

The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo.

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) Friday said that the U.S. Food and Drug Administration has granted accelerated approval to Voxzogo, the first drug approved by the FDA to improve growth in children with most common form of dwarfism. The drug has been approved to increase linear growth in pediatric patients with achondroplasia